Catalyst Wire Dossier Catalyst Wire Dossier

MK-8435-001

glycine uptake inhibitor · Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MK-8435-001, covering 2016-12-13 to 2016-12-13. Get the full timeline:

Most recent: Clinical Trial Update: Adjuvant Treatment With a Glycine Uptake Inhibitor in Participants With Negative Symptoms of Schizophrenia (P05695) (MK-8435-001) [Phase 2]

See pricing